Seres Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Seres Therapeutics reported an adjusted loss of $1.63 per share for the quarter ended September 30, compared with 94 cents per share a year earlier. Revenue rose 68.9% to $593,000, while analysts had expected $6.35 million; the company reported a $16.29 million quarterly loss.

Confirmed

Global impact / market context

Revenue growth did not prevent a much larger loss per share than analysts expected, while sales fell far short of forecasts. If revenue remains weak, Seres may have less cash available to fund its operations; the article does not provide cash reserves or a funding outlook.

Analyst inference

The reported quarter comes alongside steep share declines: 41.5% this quarter and 86.8% year to date. Analysts’ average rating is buy, but their $17 median 12-month target is a forecast, not a guarantee, and current estimates were unchanged.

Confirmed

What to watch

1. Future quarterly revenue would show whether the 68.9% year-over-year increase can continue and narrow the large gap between reported sales and analysts’ expectation. Analyst inference
2. The article says analyst earnings estimates were unchanged over three months and had no revisions in the last 30 days; subsequent revisions could reflect updated expectations. Confirmed
3. Look for company disclosures on cash available, operating costs, and funding needs; these would help assess whether continued losses require spending cuts or new financing. Analyst inference

Evidence

• Original source link unavailable